ArticleBMC cardiovascular disorders2023
Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data - the PULSE study.
Article in BMC cardiovascular disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Etiology, Management, and Outcomes of Hospitalized Heart Failure Patients:Saudi medical journal · 2026Article
- Exploration of the Pathogenesis and Treatment of Heart Failure.Reviews in cardiovascular medicine · 2026Review
- Use of soluble guanylyl cyclase stimulators in heart failure therapy-a mode of action perspective.ESC heart failure · 2026Review
- Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Observational study on initiation of dapagliflozin in heart failure with reduced ejection fraction in the United Kingdom.Frontiers in cardiovascular medicine · 2026Article
- Global heart failure incidence rate: an updated systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- The implementation of a Cardiac Scientist Led Heart Failure diagnosis clinic for non-urgent suspected heart failure referrals.Echo research and practice · 2025Article
- Observational
- Age-adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: Diagnostic accuracy study.ESC heart failure · 2025Article
- Pharmacist-led guideline-directed medical therapy in heart failure: impact analysis in primary care.BMJ open quality · 2025Article
- Men's Perceptions of Non-Cancer Related Lymphoedema: A Qualitative Diary Study.Nursing & health sciences · 2025Article
- Characterization of 2,500 Patients with Heart Failure and Analysis of Their Optimal Medical Therapy: Insights from the AMERICCAASS Registry.Global heart · 2025Observational
- Global epidemiology of heart failure.Nature reviews. Cardiology · 2024Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is associated with high morbidity and mortality, yet data on HF subtype (HF with reduced ejection fraction [HFrEF] and preserved ejection fraction [HFpEF]) in broad populations are lacking. Additionally, it is unknown whether current HF incidence and prevalence rates are consistent with historical data. Here, we estimate the incidence and prevalence of HF in England and describe the characteristics of patients with HF, both overall and by subtype.
methodsThis was a non-interventional cohort study based on data from the UK Clinical Practice Research Datalink (CPRD), linked to Hospital Episode Statistics data and Office for National Statistics mortality data. Patients aged ≥ 18 years who were registered in the CPRD Aurum database between 1
resultsThe eligible denominator over the study period comprised 11,414,490 patients, from which 383,896 patients with HF were included as prevalent or incident HF cases. From 2015 to 2019, the incidence rate of newly diagnosed HF increased from 4.1/1,000 person-years to 4.9/1,000 person-years, and HF prevalence increased from 2.1% to 2.4%. Phenotype data were available for 100,224 (26.1%) patients, of which 68,780 patients had HFrEF and 31,444 had HFpEF (HFrEF/HFpEF ratio: 70.1%/29.9%). Comorbidity levels were high and broadly similar across HF subgroups.
conclusionsPrimary care recording of HF subtype is suboptimal, with more than 7/10 patients with HF lacking subtype data. In patients with a recorded subtype (n = 100,224), a HFrEF/HFpEF ratio of 70%/30% was observed. Comorbidity levels were high regardless of subtype. Between 2015 and 2019, we observed modest but consistent increases in the incidence and prevalence of chronic HF in adults, in line with historical data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.